

# R&D for HIV/AIDS

## References

---

### Introduction

**HIV/AIDS epidemic claimed the lives of more than 32 million people; 37.9 million living with HIV/AIDS, 1.7 million people became newly infected:** UNAIDS website. Global HIV & AIDS statistics — 2019 fact sheet page. <https://www.unaids.org/en/resources/fact-sheet>. Accessed August 26, 2019.

**300+ children die every day from AIDS-related causes:** UNICEF. UNICEF Data. New York City, NY: UNICEF; 2019. <https://data.unicef.org/topic/hivaids/global-regional-trends/>. Accessed August 26, 2019.

### Research successes

**ARVs, developed with NIH support:** National Institute of Allergy and Infectious Diseases website. Antiretroviral drug discovery and development page. <https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development>. Accessed August 26, 2019.

**ARVs used to treat 21.7 million people:** UNAIDS website. Global HIV & AIDS statistics — 2019 fact sheet page. <https://www.unaids.org/en/resources/fact-sheet>. Accessed August 26, 2019.

**ARVs, averted more than 9.5 million AIDS deaths since 1995; global economic benefits of US\$1.05 trillion:** Forsythe S, McGreevey W, et al. Twenty years of antiretroviral therapy for people living with HIV: global costs, health achievements, economic benefits. *Health Affairs*. 2019;38(7). <https://doi.org/10.1377/hlthaff.2018.05391>.

**Pre-exposure prophylaxis, shown to be effective through NIH research:** National Institute of Allergy and Infectious Diseases website. Pre-exposure prophylaxis (PrEP) to reduce HIV risk page. <https://www.niaid.nih.gov/diseases-conditions/pre-exposure-prophylaxis-prep>. Accessed August 26, 2019.

**Pre-exposure prophylaxis, shown to be effective through CDC research:** Nicol M, Adams J, Kashuba A. HIV PrEP Trials: The Road to Success. *Clinical Investigation*. 2013 Mar; 3(3): 10.4155/cli.12.155. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882078/#!po=3.12500>.

Centers for Disease Control and Prevention. TDF2 Study of Pre-exposure Prophylaxis (PrEP) Among Heterosexual Men and Women in Botswana: Key Facts. Atlanta: Centers for Disease Control and Prevention; 2011: <https://www.cdc.gov/nchstp/newsroom/docs/PrEP-Heterosexuals-Factsheet.pdf>.

Garcia-Lerma JG, Paxton L, Kilmarx PH, et al. Oral pre-exposure prophylaxis for HIV prevention. *Trends in Pharmacological Science*. 2010; 31(2):74-81. <https://doi.org/10.1016/j.tips.2009.10.009>.

**Pre-exposure prophylaxis, shown to be effective through USAID research:**

Celum C. Open Label Extension studies: Findings from Partners PrEP Study. Presented at 2014 Microbicides Trial Network Regional Meeting. October 25, 2014. [https://mtnstopshiv.org/sites/default/files/attachments/CELUM-2014%20MTN%20Regional%20mtg\\_Partners%20PrEP%20OLE.pdf](https://mtnstopshiv.org/sites/default/files/attachments/CELUM-2014%20MTN%20Regional%20mtg_Partners%20PrEP%20OLE.pdf).

Clinicaltrials.gov. NCT00625404: FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women. <https://www.clinicaltrials.gov/ct2/show/NCT00625404>. Accessed January 30, 2020.

Approaches to prevent mother-to-child HIV transmission, developed with NIH support: NIH-sponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission [press release]. Bethesda, Maryland: National Institutes of Health; November 17, 2014. <https://www.nih.gov/news-events/news-releases/nih-sponsored-study-identifies-superior-drug-regimen-preventing-mother-child-hiv-transmission>.

**Approaches to prevent mother-to-child HIV transmission, 41% decline in new infections in children since 2010:**

UNAIDS website. Global HIV & AIDS statistics — 2019 fact sheet page. <https://www.unaids.org/en/resources/fact-sheet>. Accessed August 26, 2019.

**Diagnostic innovations:**

Unitaid, World Health Organization. *Market and Technology Landscape: HIV Rapid Diagnostic Tests For Self-Testing, 4<sup>th</sup> Edition*. Geneva, Switzerland: Unitaid; 2018. <https://unitaid.org/assets/HIVST-landscape-report.pdf>.

Unitaid, World Health Organization. *HIV/AIDS Diagnostics Technology Landscape, 5<sup>th</sup> Edition*. Geneva, Switzerland; 2015. [http://www.unitaid.org/assets/UNITAID\\_HIV\\_Nov\\_2015\\_Dx\\_Landscape-1.pdf](http://www.unitaid.org/assets/UNITAID_HIV_Nov_2015_Dx_Landscape-1.pdf).

**Recency testing:** PEPFAR Solution Platform (Beta) website. Surveillance of recent HIV infections: using point-of-care recency tests to rapidly detect and respond to recent infections page. <https://www.pepfarsolutions.org/emerging-technologies-innovations/2018/7/11/surveillance-of-recent-hiv-infections-using-point-of-care-recency-tests-to-rapidly-detect-and-respond-to-recent-infections>. Accessed October 17, 2019.

## Continued progress is possible, not inevitable

Bill & Melinda Gates Foundation and Institute for Health Metrics and Evaluation. *The Goalkeepers Report 2019: How Geography and Gender Stack the Deck For (or Against) You*. Seattle: Bill & Melinda Gates Foundation; 2019. <https://www.gatesfoundation.org/goalkeepers/report/2019-report/#ExaminingInequality>.

## Breakthroughs on the brink

**Microbicide vaginal ring:** IPM’s application for dapivirine vaginal ring for reducing HIV risk in women now under review by European Medicines Agency [press release]. Silver Spring, Maryland: International Partnership for Microbicides; July 13, 2017. <https://www.ipmglobal.org/content/ipm%E2%80%99s-application-dapivirine-vaginal-ring-reducing-hiv-risk-women-now-under-review-european>.

**Mosaic vaccine:** Leary, K. A vaccine for HIV is about to be tested in thousands of people. *Futurism*. November 30, 2017. <https://futurism.com/neoscope/vaccine-hiv-tested-thousands-people>.

**Two HIV vaccine candidates in late-stage clinical trials:** Engel M. New HIV vaccine study launched for World AIDS Day. *Fred Hutch News Service*. December 2, 2017. <https://www.fredhutch.org/en/news/center-news/2017/12/new-hiv-vaccine-test-launched-world-aids-day.html>.

**40 vaccine candidates in late-stage development:** Policy Cures Research. Neglected Disease R&D Product Pipeline. Sydney, Australia: Policy Cures Research; 2015. <https://www.pipeline.policycuresresearch.org/august2017>. Accessed August 26, 2019.

**Child-friendly ARV regimen:** Drugs for Neglected Diseases *initiative. Ending the Neglect of Paediatric HIV: Improving HIV Treatment for Children: An Update*. Geneva, Switzerland: Drugs for Neglected Diseases *initiative*; 2018. [https://www.dndi.org/wp-content/uploads/2018/08/DNDi\\_Paediatric-HIV\\_2018.pdf](https://www.dndi.org/wp-content/uploads/2018/08/DNDi_Paediatric-HIV_2018.pdf).

**Several clinical trials are underway to test broadly neutralizing antibodies:** AVAC. *Broadly Neutralizing Antibody Combinations*. Seattle; AVAC; 2019: <https://www.avac.org/infographic/bnab-combinations>

**BNAb developed at NIH lab:** NIH Launches Large Clinical Trials of Antibody-Based HIV Prevention [press release]. Bethesda, Maryland: National Institute of Allergy and Infectious Diseases; April 7, 2016. <https://www.niaid.nih.gov/news-events/nih-launches-large-clinical-trials-antibody-based-hiv-prevention>

**Long-acting injectable formulations of PrEP:** NIH trial evaluates long-acting HIV medication unable to adhere to strict daily regimens [press release]. Bethesda, Maryland: National Institutes of Health; May 9, 2019. <https://www.nih.gov/news-events/news-releases/nih-trial-evaluates-long-acting-hiv-medication-unable-adhere-strict-daily-regimens>.

**Multipurpose prevention products:** AVAC. *Multipurpose Prevention Technologies (MPTs): An Introductory Factsheet*. New York City, NY: AVAC; 2016. <https://www.avac.org/resource/multipurpose-prevention-technologies-mpts-introductory-factsheet>.

**Multipurpose prevention products, vaginal ring:** International Partnership for Microbicides website. Our products page. <https://www.ipmglobal.org/our-work/product-pipeline>. Accessed August 26, 2019.

**Second patient appears to be effectively cured of HIV:** Mandavilli A. H.I.V. is reported cured in a second patient, a milestone in the global AIDS epidemic. *The New York Times*. March 4, 2019. <https://www.nytimes.com/2019/03/04/health/aids-cure-london-patient.html>.

## US government investment in HIV/AIDS R&D for low-resource settings

Policy Cures Research. G-FINDER Public Search Tool. Sydney, Australia: Policy Cures Research; 2019. <https://gfinder.policycuresresearch.org/PublicSearchTool/>. [Early access to 2018 data was provided by Policy Cures Research in December 2019. Data is now available online as of January 30, 2019.]

## US government R&D efforts

Kaiser Family Foundation. *U.S. Federal Funding for HIV/AIDS: Trends Over Time*. Washington, DC: Kaiser Family Foundation; 2019. <https://www.kff.org/hivaids/fact-sheet/u-s-federal-funding-for-hivaids-trends-over-time/>.

Kaiser Family Foundation. *The U.S. Department of Defense & Global Health*. Washington, DC: Kaiser Family Foundation; 2012. <https://www.kff.org/global-health-policy/report/the-u-s-department-of-defense-global/>.

U.S. Food & Drug Administration website. President's Emergency Plan for AIDS Relief (PEPFAR) page. <https://www.fda.gov/international-programs/presidents-emergency-plan-aids-relief-pepfar>. Accessed August 26, 2019.